Literature DB >> 18789903

Helioxanthin inhibits interleukin-1 beta-induced MIP-1 beta production by reduction of c-jun expression and binding of the c-jun/CREB1 complex to the AP-1/CRE site of the MIP-1 beta promoter in Huh7 cells.

Pei-Chi Tseng1, Hsing-Chih Hsu, Damodar Janmanchi, Chih-Hsiu Lin, Yueh-Hsiung Kuo, Chen-Kung Chou, Sheau-Farn Yeh.   

Abstract

An elevated level of macrophage inflammatory protein-1beta (MIP-1beta) induced by IL-1beta has been correlated with chronic hepatic inflammatory disease. However, molecular mechanism of IL-1beta-induced MIP-1beta expression in hepatic cells is obscure. Previously, we reported the mechanism of the anti-hepatitis B virus (HBV) activity of helioxanthin (HE-145). Here, we demonstrated that HE-145 inhibited IL-1beta-induced MIP-1beta expression in a dose-dependent manner in Huh7 cells. To understand the mode of action of HE-145, we first examined how IL-1beta induced MIP-1beta expression at the molecular level. Using selective inhibitors, we found that JNK and p38 pathways participated in IL-1beta-induced MIP-1beta expression. HE-145 specifically suppressed IL-1beta-induced c-jun mRNA and protein expression and prevented c-jun-mediated AP-1 DNA-binding activity, whereas it had no effect on IL-1beta-induced activation of JNK, p38 and ATF2. Further studies indicated that HE-145 may downregulate c-jun mRNA expression directly at transcriptional level without requirement of de novo protein synthesis. Mutational analysis and supershift assays indicated that IL-1beta stimulated c-jun and CREB1 binding to the essential AP-1/CRE site of the MIP-1beta promoter. The inhibitory effect of HE-145 on IL-1beta-induced MIP-1beta promoter activity was completely reversed by overexpressing c-jun. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay consistently revealed that HE-145 reduced c-jun binding to the AP-1/CRE site in vitro and in vivo. Our results established a major role for c-jun in IL-1beta-induced MIP-1beta expression in hepatic cells. The reduction in IL-1beta-induced c-jun expression and subsequent binding of the c-jun/CREB1 complex to AP-1/CRE site mainly contributed to the inhibitory action of HE-145 on IL-1beta-induced MIP-1beta production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789903     DOI: 10.1016/j.bcp.2008.08.023

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.

Authors:  Zhicheng Lin; Ying Zhao; Chee Yeun Chung; Yanhong Zhou; Nian Xiong; Charles E Glatt; Ole Isacson
Journal:  FASEB J       Date:  2010-02-24       Impact factor: 5.191

2.  CCAAT/enhancer-binding protein β and NF-κB mediate high level expression of chemokine genes CCL3 and CCL4 by human chondrocytes in response to IL-1β.

Authors:  Zhiqi Zhang; Jennifer L Bryan; Elizabeth DeLassus; Li-Wei Chang; Weiming Liao; Linda J Sandell
Journal:  J Biol Chem       Date:  2010-08-11       Impact factor: 5.157

3.  Potent natural products and herbal medicines for treating liver fibrosis.

Authors:  Shao-Ru Chen; Xiu-Ping Chen; Jin-Jian Lu; Ying Wang; Yi-Tao Wang
Journal:  Chin Med       Date:  2015-04-15       Impact factor: 5.455

4.  Resistin stimulates expression of chemokine genes in chondrocytes via combinatorial regulation of C/EBPβ and NF-κB.

Authors:  Ziji Zhang; Zhiqi Zhang; Yan Kang; Changhe Hou; Xin Duan; Puyi Sheng; Linda J Sandell; Weiming Liao
Journal:  Int J Mol Sci       Date:  2014-09-26       Impact factor: 5.923

5.  Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.

Authors:  Yimei Que; Huimin Li; Liman Lin; Xiaojian Zhu; Min Xiao; Ying Wang; Li Zhu; Dengju Li
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

6.  Attenuation of Proinflammatory Responses by S-[6]-Gingerol via Inhibition of ROS/NF-Kappa B/COX2 Activation in HuH7 Cells.

Authors:  Xiao-Hong Li; Kristine C Y McGrath; Van H Tran; Yi-Ming Li; Colin C Duke; Basil D Roufogalis; Alison K Heather
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-16       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.